• 1
    Fisher B,Dignam J,Bryant J,Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. JNatl Cancer Inst. 2001; 93: 684690.
  • 2
    NCCN Clinical Practice Guidelines in Oncology (Version 2.2007). Available from: [Accessed May 7, 2007.]
  • 3
    Berry DA,Cirrincione C,Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295: 16581667. Erratum in:JAMA.2006;295:2356.
  • 4
    Goss PE,Ingle JN,Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 12621271.
  • 5
    Geisler J,Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95: 7581.
  • 6
    Goss P,Thomsen T,Banke-Bochita J,Lowery C,D'Angelo P,Asnis A. A randomized, placebo-controlled explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole #267 San Antonio Breast Cancer Symposium. Breast Cancer Res Treat. 2002; 76( suppl 1): S76.
  • 7
    Goss PE,Qi S,Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone. 2004; 34: 384392.
  • 8
    Macedo LF,Sabnis G,Brodie A. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer 2008; 112( 3 suppl): 681690.
  • 9
    Lu Q,Liu Y,Long BJ,Grigoryev D,Gimbel M,Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat. 1999; 57: 183192.
  • 10
    Baum M,Buzdar A,Cuzick J, et al; andThe ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone Or In Combination) trial efficacy and safety update analyses. Cancer. 2003; 98: 18021810.
  • 11
    Davidson NE,O'Neill AM,Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005; 23: 59735982.
  • 12
    Dowsett M,Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003; 86: 255263.
  • 13
    Dowsett M. Drug and hormone interactions of aromatase inhibitors. Endocr Relat Cancer. 1999; 6: 181185.
  • 14
    Goetz MP,Knox SK,Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113121.
  • 15
    Borges S,Desta Z,Li L,Skaar TC,Ward BA,Nguyen A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006; 80: 6174.
  • 16
    Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008; 112( suppl 3): 697701.
  • 17
    Sorlie T,Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 1086910874.
  • 18
    Dowsett M. The top ten research priorities in translational research in breast cancer [website]. Available at: Accessed May 2, 2007.
  • 19
    Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 28172826.
  • 20
    Paik S,Tang G,Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 37263734.
  • 21
    Habel LA,Shak S,Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8: R25.
  • 22
    Simes RJ,Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr. 2001: 146152.
  • 23
    Losordo DW,Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001; 21: 612.
  • 24
    Takei H,Lee ES,Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer. 2002; 9: 3942.
  • 25
    Ruohola JK,Valve EM,Karkkainen MJ,Joukov V,Alitalo K,Harkonen PL. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol. 1999; 149: 2940.
  • 26
    Jain RK,Safabakhsh N,Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 1998; 95: 1082010825.
  • 27
    Fan C,Oh DS,Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355: 560569.
  • 28
    Fisher B,Costantino JP,Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005; 97: 16521662.
  • 29
    Fisher B,Dignam J,Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353: 19932000.
  • 30
    Fisher B,Costantino J,Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479484.
  • 31
    Fisher B,Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr. 1992: 105116.
  • 32
    Fisher B,Bryant J,Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002; 20: 41414149.
  • 33
    Albain K BW,O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814)[abstract]. Breast Cancer Res Treat. 2004; 88( suppl 1): A-37.
  • 34
    Goss PE,Ingle JN,Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 35
    Mamounas E,Jeong JH,Wickerham L, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after five years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Presented at the 29th Annual San Antonio Breast Cancer Symposium, December 14–17, 2006, San Antonio, Texas. Breast Cancer Res Treat. 2006; 100( suppl 1): S22.
  • 36
    Fisher B,Anderson S,Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001; 19: 931942.
  • 37
    Hutchins LF,Green SJ,Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005; 23: 83138321.
  • 38
    Fisher B,Dignam J,Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996; 88: 15291542.